GRK4

Across TCGA pan-cancer cohorts, GRK4 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated GRK4 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher GRK4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GRK4 expression acts as an unfavorable survival marker.

MESO, ESCA, and SKCM are the cancer types where GRK4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	IV	0.036	0.602	<.001	42	view →
ESCA	OS	Median	II,III,IV	0.117	0.703	<.001	36	view →
SKCM	OS	Median	III,IV	0.192	0.702	.001	8	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LGG	DFS	Median	All	0.110	0.826	<.001	3	view →
COAD	OS	Median	All	0.632	0.874	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

GRK4–MESO (OS)

Open the MESO breakdown →